Company: OSRH
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-045947
Chunk: 7

Company: OSR Holdings, Inc.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 1
Chunk 7
---
 100.00%

Details
of investments in subsidiaries as of March 31, 2025 are as follows:

  Name of subsidiary  Share capital   Percentage of ownership   Principal activities  Country of 
incorporation  VAXIMM AG (“VAXIMM”)   1,091,203,754    100.00%  Biotech (drug development)  Switzerland  RMC Co., Ltd. (“RMC”)   35,000,000    100.00%  Medical device distribution  Republic of Korea  Darnatein Co., Ltd. (“Darnatein”)   6,466,667,000    100.00%  Biotech (drug development)  Republic of Korea  OSR Holdings, Inc.   2,826,969    100.00%  SPAC  The United States 

Key financial information of the subsidiaries
at March 31, 2025 are as follows :

    Name of subsidiary 
    Asset  
    Liability  
    Equity  
    Sales  
    Net Income
(loss) 
  
    VAXIMM AG 
    $910,415  
    $386,254  
    $524,161  
    $-  
    $(78,609)
  
    RMC Co.,Ltd 
     2,040,181  
     1,568,695  
     471,486  
     761,272  
     (211,541)
  
    Darnatein Co.,Ltd 
     110,171  
     678,651  
     (568,481) 
     -  
     (141,742)
  
    OSR Holdings, Inc. 
     1,687,119  
     10,071,814  
     (8,384,695) 
     -  
     - 

5

Summaries
of entities, which are newly included in consolidation scope for the periods ended March 31, 2025 and 2024 are as follows:

  For the year ended March 31, 2025  Name of subsidiary  Reason  Type of purchase consideration  OSR Holdings, Inc.  Acquisition (*1)  Equity swap with shares of the Parent and OSR inc.’s share 

(*1)The
Parent acquired subsidiary in February